Mangoceuticals, Inc. (MGRX)
Oxford Ledge is still expanding full research coverage of MGRX. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
The company exclusively relies on Epiq Scripts, owned by its CEO, for pharmacy compounding and fulfillment services under an agreement with specified geographic and operational restrictions.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-07-02
- 10-Q Quarterly financial report (unaudited) 2026-05-19
- 10-K Annual financial report with audited statements 2026-04-01
- 8-K Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-03-17
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-02-23
Source: SEC EDGAR.
Annual results
4 years of annual figures for MGRX, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $456,021 | -$20.6M | -$2.17 |
| 2024 | $615,873 | -$8.7M | -$4.80 |
| 2023 | $731,493 | -$9.2M | -$8.58 |
| 2022 | $8,939 | -$2.0M | -$0.19 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for MGRX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open MGRX in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.